Overview

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Status:
Completed
Trial end date:
2016-05-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Basilea Pharmaceutica International Ltd
Treatments:
Isavuconazole